FDA approves RHA Redensity Eye for moderate to severe undereye hollows

The FDA approved RHA Redensity Eye on August 20, 2026, for correcting moderate to severe undereye hollows in adults, giving injectors a new hyaluronic acid option engineered specifically for the highly sensitive infraorbital region. This approval expands the Teoxane RHA Collection, distributed by Revance, which expanded with a mepivacaine-formulated line in August 2025 and RHA Dynamic Volume in March 2026.

For our clinics, this provides a tool built for the unique challenges of the periorbital area, where thin skin makes swelling and superficial placement constant risks. The gel is manufactured using a heatless process called Preserved Network Technology, which preserves the natural, long-chain structure of the hyaluronic acid. In the 52-week pivotal US clinical study of patients aged 22 and older, 93 percent of subjects demonstrated aesthetic improvement at three months, and these results lasted for up to 12 months without any touch-ups.

Notably, this study was the first for a US infraorbital hyaluronic acid gel to use patient-reported outcomes as a co-primary endpoint, meaning the data directly reflects what patients actually see in the mirror. With patients regularly asking for subtle, natural-looking undereye rejuvenation, having an FDA-cleared option with proven 12-month longevity simplifies the consultation process and helps manage patient expectations. It is worth evaluating how this fits into your tear trough protocols as you plan your inventory for the coming months.

Source: Dermatology Times, https://www.dermatologytimes.com/view/fda-clears-rha-redensity-eye-for-undereye-hollows